RS55746B1 - Nova pirolopirimidinska jedinjenja kao inhibitori protein kinaza - Google Patents
Nova pirolopirimidinska jedinjenja kao inhibitori protein kinazaInfo
- Publication number
- RS55746B1 RS55746B1 RS20170228A RSP20170228A RS55746B1 RS 55746 B1 RS55746 B1 RS 55746B1 RS 20170228 A RS20170228 A RS 20170228A RS P20170228 A RSP20170228 A RS P20170228A RS 55746 B1 RS55746 B1 RS 55746B1
- Authority
- RS
- Serbia
- Prior art keywords
- inhibitors
- protein kinases
- pyrrolopyrimidine compounds
- novel pyrrolopyrimidine
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680231P | 2012-08-06 | 2012-08-06 | |
US13/843,554 US9034885B2 (en) | 2012-01-13 | 2013-03-15 | EGFR modulators and uses thereof |
US201361814147P | 2013-04-19 | 2013-04-19 | |
US13/917,514 US8685988B2 (en) | 2012-08-06 | 2013-06-13 | EGFR modulators and uses thereof |
EP13745491.4A EP2880035B9 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
PCT/US2013/050163 WO2014025486A1 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
RS55746B1 true RS55746B1 (sr) | 2017-07-31 |
Family
ID=50026061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20170228A RS55746B1 (sr) | 2012-08-06 | 2013-07-11 | Nova pirolopirimidinska jedinjenja kao inhibitori protein kinaza |
Country Status (4)
Country | Link |
---|---|
US (5) | US9034885B2 (sr) |
PL (1) | PL2880035T3 (sr) |
RS (1) | RS55746B1 (sr) |
SI (1) | SI2880035T1 (sr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10799504B2 (en) * | 2012-01-13 | 2020-10-13 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses as anticancer agents |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
CN105916851A (zh) | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
EP3253750B1 (en) | 2015-02-03 | 2019-04-10 | Council of Scientific and Industrial Research | Novel flavone based egfr inhibitors and process for preparation thereof |
CA2976109A1 (en) | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors |
CN107949388B (zh) * | 2015-10-09 | 2021-10-26 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
CN111212837A (zh) | 2017-04-07 | 2020-05-29 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
UY37935A (es) * | 2017-10-18 | 2020-03-31 | Spectrum Pharmaceuticals Inc | Inhibidores de tirosina quinasas de la familia de los egfr mutantes |
US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
WO2023209084A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974277A (en) | 1974-09-06 | 1976-08-10 | Diamond Shamrock Corporation | 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents |
JPS55105836A (en) | 1979-01-31 | 1980-08-13 | Sharp Corp | Lock releasing device for tape recorder |
JPS59213282A (ja) | 1983-05-19 | 1984-12-03 | Shiyouta Miyairi | 相間リアクトル付き多重相の電力変換回路における高調波及び脈動の低減回路 |
EP1230225A2 (en) | 1999-11-01 | 2002-08-14 | Eli Lilly And Company | Pharmaceutically active 4-substituted pyrimidine derivatives |
EP1369418B1 (en) | 2001-02-21 | 2010-07-28 | Mitsubishi Tanabe Pharma Corporation | Quinazoline derivatives |
US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
WO2003026665A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
AU2003267998A1 (en) | 2002-07-20 | 2004-02-09 | Acea Biosciences, Inc. | Impedance based devices and methods for use in assays |
US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
KR20040042896A (ko) | 2002-11-15 | 2004-05-20 | 미쯔비시 웰 파마 가부시키가이샤 | 의약 제제 조성물 |
CA2550274A1 (en) | 2003-11-12 | 2005-05-26 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
WO2005066156A1 (en) | 2004-01-12 | 2005-07-21 | Cytopia Research Pty Ltd | Selective kinase inhibitors |
CN1997644A (zh) | 2004-03-02 | 2007-07-11 | 神经能质公司 | 被芳基取代的嘌呤类似物 |
WO2006009755A2 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
ES2381962T3 (es) | 2005-09-21 | 2012-06-04 | 4Sc Ag | Nuevos sulfonilpirroles como inhibidores de las HDAC |
EP1948658A1 (en) | 2005-10-13 | 2008-07-30 | Glaxo Group Limited | Pyrrolopyrimidine derivatives as syk inhibitors |
KR100832593B1 (ko) | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
GB0526246D0 (en) | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
EP2010183A4 (en) | 2006-03-03 | 2010-08-25 | Aveo Pharmaceuticals Inc | PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND |
EP2007373A4 (en) | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
WO2008039359A2 (en) | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
EP2091918B1 (en) | 2006-12-08 | 2014-08-27 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CN101622001A (zh) | 2007-01-26 | 2010-01-06 | Irm责任有限公司 | 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物 |
WO2008092199A1 (en) | 2007-01-31 | 2008-08-07 | Cytopia Research Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009020990A1 (en) | 2007-08-08 | 2009-02-12 | Smithkline Beecham Corporation | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
CA2723185A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
WO2010045451A1 (en) | 2008-10-16 | 2010-04-22 | Glaxosmithkline Llc | Pyrrolopyrimidine compounds |
US20100204221A1 (en) | 2009-02-09 | 2010-08-12 | Hariprasad Vankayalapati | Pyrrolopyrimidinyl axl kinase inhibitors |
EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
US20130137709A1 (en) | 2010-05-05 | 2013-05-30 | Nathanael S. Gray | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith |
SG186378A1 (en) | 2010-06-23 | 2013-01-30 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
CN102583089B (zh) | 2011-01-11 | 2015-11-25 | 山东新北洋信息技术股份有限公司 | 薄片类介质处理装置 |
CN103619873A (zh) | 2011-03-07 | 2014-03-05 | 泰莱托恩基金会 | Tfeb变体及其应用 |
EP2694486B1 (en) | 2011-04-01 | 2018-01-10 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
US9034885B2 (en) * | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US10799504B2 (en) | 2012-01-13 | 2020-10-13 | ACEA Therapeutics, Inc. | Heterocyclic compounds and uses as anticancer agents |
US9586965B2 (en) * | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
SI3459942T1 (sl) | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
JP6215938B2 (ja) | 2012-08-06 | 2017-10-18 | エイシア バイオサイエンシーズ インコーポレイテッド | プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物 |
CN105916851A (zh) | 2013-07-11 | 2016-08-31 | 艾森生物科学公司 | 嘧啶衍生物作为激酶抑制剂 |
CN104306348B (zh) | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | 一种辛伐他汀片及其制备方法 |
CN107949388B (zh) | 2015-10-09 | 2021-10-26 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
CN111212837A (zh) | 2017-04-07 | 2020-05-29 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
-
2013
- 2013-03-15 US US13/843,554 patent/US9034885B2/en active Active
- 2013-06-13 US US13/917,514 patent/US8685988B2/en active Active
- 2013-07-11 PL PL13745491T patent/PL2880035T3/pl unknown
- 2013-07-11 RS RS20170228A patent/RS55746B1/sr unknown
- 2013-07-11 SI SI201330554A patent/SI2880035T1/sl unknown
-
2015
- 2015-05-14 US US14/712,794 patent/US9763949B2/en active Active
-
2017
- 2017-09-18 US US15/708,024 patent/US10449196B2/en active Active
-
2019
- 2019-09-30 US US16/587,110 patent/US11007197B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8685988B2 (en) | 2014-04-01 |
US20200129516A1 (en) | 2020-04-30 |
US9034885B2 (en) | 2015-05-19 |
US11007197B2 (en) | 2021-05-18 |
US20150246047A1 (en) | 2015-09-03 |
US20180008607A1 (en) | 2018-01-11 |
US9763949B2 (en) | 2017-09-19 |
US10449196B2 (en) | 2019-10-22 |
US20140038981A1 (en) | 2014-02-06 |
SI2880035T1 (sl) | 2017-05-31 |
PL2880035T3 (pl) | 2017-07-31 |
US20140038940A1 (en) | 2014-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201600648B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
HRP20190128T1 (hr) | Novi spojevi kao modulatori protein kinaza | |
IL263262B (en) | Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation | |
IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
PL2880035T3 (pl) | Nowe związki pirolopirymidynowe jako inhibitory kinaz białkowych | |
HK1215253A1 (zh) | 作為激酶抑制劑的吡咯並嘧啶化合物 | |
HK1215578A1 (zh) | 作為蛋白激酶抑制劑的氮雜吲哚衍生物 | |
HK1210598A1 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- | |
IL243729A0 (en) | Novel modulators of protein kinases |